Clinical Benefit of Adjunctive Rituximab in Anti–Interferon-Gamma Autoantibody-Associated Immunodeficiency: A Retrospective Self-Controlled Cohort Study

Clicks: 5
ID: 338075
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #310 of 318 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 318 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Antimicrobial therapy is the cornerstone of treatment for anti–interferon-gamma (IFN-γ) autoantibody-associated immunodeficiency (AOID), but persistent or relapsing infections remain challenging. We evaluated outcomes associated with adjunctive rituximab in patients with AOID. Methods We conducted a retrospective self-controlled cohort study of adult patients with AOID treated at a tertiary care hospital in Northern Thailand between January 2019 and December 2024. Each patient contributed data from two treatment periods: antimicrobial therapy alone and with adjunctive rituximab. Clinical and laboratory outcomes were compared over three-month observation windows. Results Among 14 patients with AOID, the mean age was 61.00 ± 8.84 years, and 6 patients (42.86%) were male. NTM infection was present in all patients. Rapidly growing mycobacteria (RGM) infections were the predominant NTM infections in both treatment periods, occurring in 13 patients (92.86%). Compared with the antimicrobial-only period, adjunctive rituximab was associated with a significantly higher likelihood of successful antimicrobial de-escalation (adjusted odds ratio, 5.38; 95% confidence interval [CI], 1.16–25.00; P = .032). Rituximab exposure was also associated with a greater reduction in absolute lymphocyte count (adjusted β, −379 cells/µL; 95% CI, −725 to −33; P = .032) and a modest increase in alkaline phosphatase (adjusted β, 32.8 U/L; 95% CI, 8.7–56.9; P = .008). No rituximab-associated infusion reactions, hypersensitivity reactions, severe infections related to immunosuppression, or deaths were observed. Conclusion Adjunctive rituximab was associated with a higher likelihood of successful antimicrobial de-escalation without major short-term safety concerns. Further prospective evaluation is warranted.
Reference Key
openalex_W7224965343 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kanokkarn Pinyopornpanish, Wannada Laisuan, Romanee Chaiwarith, Harit Thongwitokomarn, Sutina Laimangkorn, Phichayut Phinyo, Kanokporn Pinyopornpanish
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag704
URL
https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofag704/72615058/ofag704.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.